Save the date: 16 - 18 October 2023, Rio de Janeiro, Brazil!

Identifying and preventing morbidity and mortality caused by Streptococcus agalactiae (Group B Strep).

The next ISSAD 2023 promises to be an interactive and comprehensive platform covering topics ranging from the GBS disease burden and challenges to the epidemiology, immunology and vaccinology of GBS and everything in between.

We encourage you to share graphics, social media posts, and information about #ISSAD2023 with your networks. Access our Social Media Toolkit where you'll find shareable graphics. Be sure to tag @IssadOrg.

Young ISSAD Committee Blog

The Young ISSAD Committee has created a new blog for the website, located in the News & Events section at www.issad.org.

This months feature is a downloadable infographic on ‘Signs & Symptoms of GBS in Newborns’ by Javairia Khalid, Lecturer at The Aga Khan University, Pakistan.

Announcements & Events..

‘Young ISSAD’ Committee..

The ‘Young ISSAD’ Committee will continue to run a series of events and discussions on LinkedIn and Zoom. Please keep an eye out on our website and social media for updates.

'Young ISSAD' Seminar Series

22nd June 2023 - GBS under one health perspective

Whether you are a student, early career researcher or academic. All welcome!

International Prenatal Infection Prevention Month

Group B Strep International is proud to sponsor February as International Prenatal Infection Prevention Month. Check out their toolkit for resources and social media posts to help educate people on how to help prevent prenatal infections year-round.

Read more here Group B Strep International.

Present your research at the virtual Group B Strep in Pregnancy & Babies 2023 Conference – Wednesday 17 May 2023

Abstracts are now being accepted for the above annual virtual conference, which brings together experts from the UK and around the world to share knowledge and discuss the latest developments in this field. This conference will provide a platform for researchers to present the latest findings in Group B Strep in pregnancy and babies, as well as an opportunity to network with peers and share best practices. We are particularly interested in research on GBS and epidemiology, vaccines, microbiology and testing, and clinical care relating to GBS in pregnant women and their newborns.

All accepted abstracts will have the opportunity to be published without charge (usual APC $1,700) in the SAGE peer-reviewed gold open access journal Therapeutic Advances in Infectious Disease, and up to four authors will be invited to pre-record a short presentation about their work for the conference. The submission deadline is midnight on Friday 10 March 2023.

There’s more information about the conference here and information about abstract submission here.

MinervaX announces 72M EUR financing to advance development of novel vaccine against Group B Streptococcus

MinervaXApS, a privately held Danish biotechnology company developing a novel vaccine against Group B Streptococcus (GBS), today announces the successful completion of a 72 million EUR financing round. The equity financing of 22 million EUR was co-led by new investors Trill Impact Ventures and Pureos Bioventures and includes existing investors REPAIR Impact Fund (Novo Holdings), Sunstone Life Science Ventures, LF Investment, Wellington Partners, Sanofi Ventures, Adjuvant Capital and Industrifonden. In addition to the equity financing, theEuropean Investment Bankprovided a 50 million EUR loan facility.